In 2013, Histogen and its joint venture partner formed PUR Biologics, LLC, a company focused on development of regenerative biologic solutions to address musculoskeletal surgical needs, including spine, dental, ligament and medical device coating applications. Histogen has licensed its CCM and ECM materials to PUR for orthopedic applications, and PUR’s lead product for cartilage repair has demonstrated strong efficacy in a large animal preclinical safety and efficacy study. This future product, based on Histogen’s proprietary ECM, has enormous future market potential to address the loss of cartilage in knees and other joints associated with age, as well as spinal disc degeneration, osteoarthritis, sports injury, and other tissue damage. PUR is also developing a holding solution for hydrating and implant conditioning
Histogen has been awarded grants from the National Science Foundation (NSF) to develop its ECM material, in combination with an antimicrobial peptide technology, for the treatment of chronic wounds. The Company has developed a wafer comprised of its ECM coated with the antimicrobial peptide which can be placed in a wound bed to simultaneously aid in tissue regeneration, prevent infection and reduce inflammation. The initial focus of the work under these grants is in the treatment of chronic wounds, specifically diabetic, venous and pressure ulcers
For more information, please visit our Business Development page.